Harrison.ai vs Rayscape (2026)
Two comprehensive chest radiograph platforms, both claiming to read for a very large number of findings, and the comparison should not be run on that number. Annalise, now sold as Harrison.ai, is the more established, carrying regulatory footprints across multiple markets and more than a third of NHS England chest X-rays. Rayscape is smaller and has the more interesting evidence: independent evaluation in a tuberculosis screening setting, which is a harder test than a reader study because the deployment is exactly where radiologist capacity is thinnest and the consequence of a miss is highest. It also adds longitudinal comparison across prior scans and offers on premise deployment. For a hospital standardizing across sites, Annalise carries fewer unknowns. For a screening program, Rayscape has been tested in something resembling the real conditions.
- The comprehensive chest radiograph position is established across a large findings set with regulatory footprints in multiple markets and more than a third of NHS England chest X-rays.
- Deployment maturity is greater, which matters for a modality where the failure mode is a subtle finding missed at scale rather than a dramatic error.
- For a health system standardizing chest radiograph AI across sites, the more widely deployed platform carries fewer unknowns.
- The evidence includes independent evaluation in a tuberculosis screening context, which is a harder and more consequential test than a retrospective reader study.
- Findings breadth on chest radiography is substantial and the platform adds longitudinal comparison across a patient's prior scans, so change over time is visible rather than each study read in isolation.
- Both on premise and cloud integration are offered, which matters where images cannot leave the institution or the country.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Harrison.ai and Rayscape are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Harrison.ai | Rayscape |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2019 | 2019 |
| Headquarters | Sydney, Australia | Timisoara, Romania |
| Website | harrison.ai | rayscape.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Harrison.ai, headquartered in Sydney, sells radiology AI that until 2025 was sold under the Annalise.ai name. Harrison.ai combined with Annalise.ai in February 2025 and renamed the Annalise products in October 2025, and the annalise.ai domain now forwards to harrison.ai.
Source: AI Health Index, August 2026
Romanian imaging AI company based in Timisoara whose Rayscape CXR analyzes chest X-rays, detecting and localizing 148 findings across 17 clinical classes, including tuberculosis, with bone suppressed views, an automatic cardiothoracic ratio and a normal or abnormal flag for worklist prioritization, and whose lung CT product detects nodules and compares them against a patient's prior scans. Its tuberculosis detection was evaluated independently in a South African tuberculosis prevalence survey published in The Lancet Digital Health in 2024.
Source: AI Health Index, August 2026
Questions buyers ask
How do Harrison.ai and Rayscape work with the EHR?
For Harrison.ai, the 510(k) summary for K222268 describes the software receiving DICOM chest X-ray studies from image and order management systems such as a PACS or RIS, running in parallel with the standard workflow, and returning a case level result to the PACS or RIS for worklist prioritization.
Rayscape CXR integrates with the archive over DICOM, on premises or with a cloud archive, returning annotated images and structured outputs inside the native radiology viewer without a separate workspace, and sites can configure outputs, thresholds and visualization to their own reporting standards. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Harrison.ai and Rayscape priced and sold?
In Harrison.ai's case, the products are sold to healthcare organizations (public hospitals, private hospitals and private radiology providers) by contacting the company, and the site states they are not available for purchase by the general public.
The company's site has a pricing and plans page, and its AWS Marketplace listing for Rayscape CXR shows a free subscription with no end date alongside a 30 day money back guarantee on the current annual term, which suggests a paid annual contract behind the listing without stating its price or unit. The product can be procured through the marketplace and directly. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Harrison.ai and Rayscape handle patient data?
With Harrison.ai, the company's privacy notice (last updated 20 November 2025), which covers its products and services as well as its websites, states that it does not use any content uploaded into its services, including demos, product trials and evaluations, for model training.
In Rayscape's case, the company's AWS Marketplace listing describes the product as software as a service, which sits uneasily with data never leaving the institution, and nothing says which deployments the commitment covers. Support, diagnostic and incident access usually carries exceptions. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Harrison.ai and Rayscape cover?
For Harrison.ai, the company sells chest X-ray (up to 124 findings), non contrast head CT (up to 130 findings) and chest CT (up to 167 radiological features) to public hospitals, private hospitals and private radiology providers, with solution pages for emergency and acute care and for oncology management, and states clearance for clinical use in more than 40 countries. The US triage clearances carry defined, validated populations.
With Rayscape, the tuberculosis use has independent validation in a South African prevalence survey (The Lancet Digital Health, 2024), a population screening setting; the broader findings set and the CT product have no published per finding validation. The company reports clinical use at more than 300 sites in 18 countries, and its customer stories describe emergency and outpatient deployments. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Comprehensive chest radiograph products claim large numbers of findings and those numbers are not comparable across vendors, because each counts differently and the per finding performance varies enormously within any such list. Ask both for performance on the specific findings that matter in your population rather than for the headline count. Neither vendor publishes a security attestation on its main site, though Harrison.ai, formerly Annalise, runs a trust center.
Prevalence is the other uncontrolled variable: a model validated in a high tuberculosis burden setting will produce very different positive predictive values in a low prevalence one, and neither vendor publishes performance stratified that way.